{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T08:48:04Z","timestamp":1782204484299,"version":"3.54.5"},"reference-count":22,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Self-selected Project of Fuwai Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College","award":["T2023-ZX017"],"award-info":[{"award-number":["T2023-ZX017"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Right heart failure is a life-threatening complication of pulmonary hypertension (PH), with limited treatment options. Although recombinant human brain natriuretic peptide (rhBNP) is widely used in left heart failure, its effectiveness in right heart failure associated with varying groups of PH (Groups 1, 2, and 4) is unknown. Materials and Methods: 763 patients with varying groups of PH (PH Groups 1, 2, and 4) were enrolled and received both conventional therapy and rhBNP treatment. Therapeutic efficacy and adverse event incidence were evaluated among the PH groups. Results: Significant reductions in variables reflecting cardiac congestion, including NT-proBNP, total bilirubin, and body weight, were observed in all PH subgroups (all p &lt; 0.001). The median percentage changes were \u221247% (IQR \u221276 to \u221224), \u221221% (IQR \u221233 to \u22121), and \u22123% (IQR \u22127 to \u22121), respectively. Alanine transaminase levels presented a decreasing trend (p &lt; 0.001), whereas creatinine levels remained unchanged (p &gt; 0.05), with consistent trends across PH subgroups. The hemodynamic response was heterogeneous, with marked decreases in the mean arterial pressure in Groups 1 and 4 (p &lt; 0.001) but not in Group 2. Improvement in dyspnea and edema of the lower limbs was observed in 49.9% and 66.6% of cases, respectively. The overall incidence of adverse events was 0.66%, with 0.26% (2\/763) being serious, all of which were in Group 1 PH. Conclusions: Findings from this exploratory analysis indicated that rhBNP treatment was associated with favorable changes in congestive status and clinical symptoms across different PH subgroups, as well as stable end-organ function. Of note, all patients received comprehensive conventional background therapy; thus, these improvements cannot be exclusively attributed to rhBNP alone. Given the observed hemodynamic fluctuations, close blood pressure monitoring should be considered throughout the treatment course, particularly for patients in Groups 1 and 4, and most notably for high-risk PAH patients (Group 1 PH).<\/jats:p>","DOI":"10.3390\/medicina62071213","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:13:37Z","timestamp":1782195217000},"page":"1213","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective Evaluation of Recombinant Human Brain Natriuretic Peptide Therapy for Decompensated Right Heart Failure Across Pulmonary Hypertension Groups"],"prefix":"10.3390","volume":"62","author":[{"given":"Lixing","family":"Hu","sequence":"first","affiliation":[{"name":"Center for Respiratory and Pulmonary Vascular Diseases, Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Center for Respiratory and Pulmonary Vascular Diseases, Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Center for Respiratory and Pulmonary Vascular Diseases, Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Luo","sequence":"additional","affiliation":[{"name":"Center for Respiratory and Pulmonary Vascular Diseases, Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Deng","sequence":"additional","affiliation":[{"name":"Center for Respiratory and Pulmonary Vascular Diseases, Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Respiratory and Pulmonary Vascular Diseases, Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1164\/rccm.202302-0327SO","article-title":"Pulmonary hypertension: A contemporary review","volume":"208","author":"Johnson","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"ITC49","DOI":"10.7326\/AITC202104200","article-title":"Pulmonary hypertension","volume":"174","author":"Poch","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMp020057","article-title":"B-type natriuretic peptide\u2014A window to the heart","volume":"347","author":"Baughman","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Potter, L.R., Yoder, A.R., Flora, D.R., Antos, L.K., and Dickey, D.M. (2009). Natriuretic peptides: Their structures, receptors, physiologic functions and therapeutic applications. Handbook of Experimental Pharmacology, Springer.","DOI":"10.1007\/978-3-540-68964-5_15"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1471-4892(02)00142-X","article-title":"B-type natriuretic peptide for the treatment of congestive heart failure","volume":"2","author":"Schreiner","year":"2002","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1517\/13543784.8.7.1063","article-title":"Therapeutic potential of nesiritide (recombinant b-type natriuretic peptide) in the treatment of heart failure","volume":"8","author":"Hobbs","year":"1999","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Committee for the VMAC Investigators (2002). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA, 288, 577.","DOI":"10.1001\/jama.288.5.571-a"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e8545","DOI":"10.1136\/bmjopen-2015-008545","article-title":"Efficacy and safety of nesiritide in patients with decompensated heart failure: A meta-analysis of randomised trials","volume":"6","author":"Gong","year":"2016","journal-title":"BMJ Open"},{"key":"ref_9","first-page":"757","article-title":"Observation on the Short-Term Efficacy of Lyophilized Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Intractable Heart Failure Complicated with Pulmonary Hypertension","volume":"22","author":"Zhao","year":"2018","journal-title":"Anhui Med. Pharm. J."},{"key":"ref_10","first-page":"629","article-title":"Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Heart Failure Complicated with Pulmonary Hypertension","volume":"623\u2013625","author":"Mao","year":"2015","journal-title":"Chronic Pathematology J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cardfail.2005.01.009","article-title":"Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension","volume":"11","author":"Michaels","year":"2005","journal-title":"J. Card. Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1536\/ihj.21-086","article-title":"Effects of recombinant human brain natriuretic peptide in patients with acute pulmonary embolism complicated with right ventricular dysfunction who underwent catheter-directed therapy","volume":"63","author":"Meng","year":"2022","journal-title":"Int. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.cardfail.2006.05.004","article-title":"Nesiritide acutely increases pulmonary and systemic levels of nitric oxide in patients with pulmonary hypertension","volume":"12","author":"Khush","year":"2006","journal-title":"J. Card. Fail."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"72S","DOI":"10.1378\/chest.114.1_Supplement.72S","article-title":"Endothelial dysfunction providing the basis for the treatment of pulmonary hypertension: Giles f. Filley lecture","volume":"114","author":"Higenbottam","year":"1998","journal-title":"Chest"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1802148","DOI":"10.1183\/13993003.02148-2018","article-title":"An overview of the 6th world symposium on pulmonary hypertension","volume":"53","author":"Mclaughlin","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 esc\/ers guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_17","first-page":"782","article-title":"Effectiveness and safety of Recombinant Human Brain Natriuretic Peptide for the Treatment of Patients with Right Heart Failure caused by Pulmonary Arterial Hypertension","volume":"40","author":"Hu","year":"2025","journal-title":"Chin. Circ. J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Takeda, Y., Takeda, Y., Tomimoto, S., Tani, T., Narita, H., and Kimura, G. (2010). Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension. BMC Pulm. Med., 10.","DOI":"10.1186\/1471-2466-10-22"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1378\/chest.117.1.19","article-title":"Hyperuricemia in severe pulmonary hypertension","volume":"117","author":"Voelkel","year":"2000","journal-title":"Chest"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","article-title":"Uric acid and risk of heart failure: A systematic review and meta-analysis","volume":"16","author":"Huang","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Yan, L., Huang, Z., Zhao, Z., Zhao, Q., Tang, Y., Zhang, Y., Li, X., Duan, A., Luo, Q., and Liu, Z. (2022). The prognostic impact of serum uric acid on disease severity and 5-year mortality in patients with idiopathic pulmonary artery hypertension. Front. Med., 9.","DOI":"10.3389\/fmed.2022.805415"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1183\/09031936.00070209","article-title":"Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension","volume":"35","author":"Sztrymf","year":"2010","journal-title":"Eur. Respir. J."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1213\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T08:00:16Z","timestamp":1782201616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["medicina62071213"],"URL":"https:\/\/doi.org\/10.3390\/medicina62071213","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}